WO2005115147A3 - Hiv reverse transcriptase inhibitors - Google Patents
Hiv reverse transcriptase inhibitors Download PDFInfo
- Publication number
- WO2005115147A3 WO2005115147A3 PCT/US2005/016671 US2005016671W WO2005115147A3 WO 2005115147 A3 WO2005115147 A3 WO 2005115147A3 US 2005016671 W US2005016671 W US 2005016671W WO 2005115147 A3 WO2005115147 A3 WO 2005115147A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivatives
- reverse transcriptase
- hiv reverse
- hiv
- transcriptase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
Abstract
Tetrazolyl derivatives of Formula (I): are HIV reverse transcriptase inhibitors, wherein U is O, S(O)n where n is an integer equal to zero, 1 or 2, or N(R4); V is optionally substituted C1-8 alkylene; W is C(O)N(R2) or a direct bond linking V to R3; and R1, R2, R3 and R4 are defined herein. The derivatives of Formula I are useful in the inhibition of HIV reverse transcriptase, the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The derivatives are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The derivatives and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57216804P | 2004-05-18 | 2004-05-18 | |
| US60/572,168 | 2004-05-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005115147A2 WO2005115147A2 (en) | 2005-12-08 |
| WO2005115147A3 true WO2005115147A3 (en) | 2007-04-19 |
Family
ID=35451352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/016671 WO2005115147A2 (en) | 2004-05-18 | 2005-05-12 | Hiv reverse transcriptase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005115147A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517998B2 (en) * | 2004-06-01 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Non nucleoside reverse transcriptase inhibitors |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| WO2008070994A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| US20120122889A1 (en) | 2008-12-23 | 2012-05-17 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
| CN104817509B (en) * | 2015-04-13 | 2019-05-17 | 安徽省逸欣铭医药科技有限公司 | Lesinurad analog and preparation method thereof and medical usage |
| GB201602572D0 (en) | 2016-02-12 | 2016-03-30 | Eriksson Leif And Strid Ake And Sirsjö Allan | New compound and uses |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540703A (en) * | 1978-09-07 | 1985-09-10 | Otsuka Pharmaceutical Company, Limited | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers |
| WO2004030611A2 (en) * | 2002-08-23 | 2004-04-15 | Ribapharm Inc. | Non-nucleoside reverse transcriptase inhibitors |
| WO2004050643A2 (en) * | 2002-12-04 | 2004-06-17 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
-
2005
- 2005-05-12 WO PCT/US2005/016671 patent/WO2005115147A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540703A (en) * | 1978-09-07 | 1985-09-10 | Otsuka Pharmaceutical Company, Limited | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers |
| WO2004030611A2 (en) * | 2002-08-23 | 2004-04-15 | Ribapharm Inc. | Non-nucleoside reverse transcriptase inhibitors |
| WO2004050643A2 (en) * | 2002-12-04 | 2004-06-17 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE REGISTRY [online] 11 May 2001 (2001-05-11) * |
| DATABASE REGISTRY [online] 18 January 2002 (2002-01-18) * |
| DATABASE REGISTRY [online] 21 December 2000 (2000-12-21) * |
| DATABASE REGISTRY [online] 22 January 2002 (2002-01-22) * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005115147A2 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2020026I1 (en) | Raltegravir or a pharmaceutically acceptable salt thereof, especially the potassium salt | |
| BR0317749A (en) | Compound, pharmaceutical composition, and use of a compound | |
| WO2007146230A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2005086700A3 (en) | Hiv integrase inhibitors | |
| WO2004024078A3 (en) | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | |
| WO2006121831A3 (en) | Hiv integrase inhibitors | |
| ATE355064T1 (en) | DIHYDROXYPYRIMIDINE CARBONIC ACID RAMIDE INHIBITORS OF HIV INTEGRASE | |
| WO2005120516A3 (en) | Hiv integrase inhibitors | |
| WO2005074513A3 (en) | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors | |
| WO2007015812A3 (en) | Hiv reverse transcriptase inhibitors | |
| WO2005110414A3 (en) | Hiv integrase inhibitors | |
| MX2009006285A (en) | Non-nucleoside reverse transcriptase inhibitors. | |
| WO2008054605A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2007050510A3 (en) | Hiv integrase inhibitors | |
| WO2005115147A3 (en) | Hiv reverse transcriptase inhibitors | |
| AU2006299042A8 (en) | HIV integrase inhibitors | |
| WO2009042094A3 (en) | Hiv protease inhibitors | |
| WO2003077850A3 (en) | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors | |
| WO2007002458A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2004047725A3 (en) | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | |
| WO2007002481A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2007002368A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| TW200640460A (en) | HIV integrase inhibitors | |
| TNSN06270A1 (en) | Hiv integrase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |